Medgenics (MDGN) - NYSEMKT
  • Tue, Jun. 21, 12:48 PM
    | Tue, Jun. 21, 12:48 PM | 12 Comments
  • Tue, Jun. 21, 11:00 AM
    | Tue, Jun. 21, 11:00 AM | 1 Comment
  • Tue, Jun. 21, 9:12 AM
    | Tue, Jun. 21, 9:12 AM
  • Fri, Jun. 17, 8:36 AM
    • Gene therapy firm Medgenics (NYSEMKT:MDGN) has enrolled the first patient in its Phase 2/3 clinical trial, SAGA, assessing lead product candidate NFC-1 in adolescent patients with attention deficit hyperactivity disorder (ADHD).
    • The double-blind, placebo-controlled study will recruit 90 ADHD patients between the ages of 12 and 17 years who have genetic disorders impacting the mGluR (metabotropic glutamate receptor) network. Participants will be randomized 1:1 to receive either a six-week course of NFC-1 or placebo, with a one-week follow-up. The primary endpoint is the change from baseline in the ADHD-rating scale (ADHD-RS-5) Total Score to Visit 8 (Week 6). According to ClinicalTrials.gov, the estimated final data collection date for the primary endpoint is October. The estimated study completion date is November.
    • Small molecule NFC-1 is an mGluR modulator that is based on a technology called Transduced Autologous Restorative Gene Therapy ((TARGT)). According to the company, TARGT enables greater cell uptake, less immunogenicity, improved safety and tolerability and lower cost than other gene therapies.
    • MGluRs are a family of protein receptors that bind to glutamate, an amino acid that plays a key role in neurotransmission. Manipulating mGluRs is being investigated for the potential treatment of certain cancers, Parkinson's disease, anxiety disorders, autism and schizophrenia.
    | Fri, Jun. 17, 8:36 AM
  • Tue, May 10, 8:15 AM
    • Medgenics (NYSEMKT:MDGN): Q1 EPS of -$0.34 misses by $0.08.
    • Cash and cash equivalents of $43.9M.
    • Press Release
    | Tue, May 10, 8:15 AM
  • Wed, Feb. 17, 9:54 AM
    • Medgenics (MDGN +5.8%) Q4 results: Revenues: $0; R&D Expense: $4.3M (+13.2%); SG&A: $2.1M (-12.5%); Net Loss: ($6.5M) (-4.8%); Loss Per Share: ($0.20) (+33.3%).
    • FY2015 results: Revenues: $0; R&D Expense: $15.4M (+85.5%); SG&A: $13M (+21.5%); Operating Loss: ($36.6M) (-93.7%); Net Loss: ($38M) (-106.5%); Loss Per Share: ($1.55) (-55.0%); Quick Assets: $33.3M (-37.3%).
    • No guidance given.
    | Wed, Feb. 17, 9:54 AM
  • Wed, Feb. 17, 8:04 AM
    | Wed, Feb. 17, 8:04 AM
  • Oct. 22, 2015, 10:34 AM
    • Medgenics (MDGN -0.3%) Q3 results: Revenues: $0; R&D Expense: $4.2M (+162.5%); SG&A: $3M (+30.4%); Operating Loss: ($15.4M) (-294.9%); Net Loss: ($16.5M) (-450.0%); Loss Per Share: ($0.66) (-214.3%); Quick Assets: $17.7M (-46.8%).
    • No guidance given.
    | Oct. 22, 2015, 10:34 AM
  • Oct. 22, 2015, 8:05 AM
    • Medgenics (NYSEMKT:MDGN): Q3 EPS of -$0.66
    | Oct. 22, 2015, 8:05 AM
  • Oct. 7, 2015, 6:57 PM
    • Medgenics (NYSEMKT:MDGN) commences a public of common stock. Price, volume and terms have yet to be announced.
    • Shares are unchanged in after hours trading.
    | Oct. 7, 2015, 6:57 PM
  • Oct. 1, 2015, 12:40 PM
    | Oct. 1, 2015, 12:40 PM | 1 Comment
  • Oct. 1, 2015, 9:00 AM
    • Medgenics (NYSEMKT:MDGN) is down 14% premarket on light volume in response to its announcement of a public offering of common stock. Price, volume and terms have yet to be announced.
    | Oct. 1, 2015, 9:00 AM
  • Aug. 10, 2015, 5:03 PM
    • Medgenics (NYSEMKT:MDGN): Q2 EPS of -$0.28 beats by $0.03.
    | Aug. 10, 2015, 5:03 PM
  • Jul. 15, 2015, 8:20 AM
    • Medgenics (NYSEMKT:MDGN) announces that the first patient has been enrolled in a Phase 2 clinical trial evaluating MDGN-201 (TARGTepo) for the treatment of anemia in patients with end stage renal disease undergoing peritoneal dialysis.
    • The primary endpoint of the 12-subject open label study is the maintenance of hemoglobin within the range of 9 - 12 g/dL for 52 weeks. The estimated completion date is September 2017.
    • MDGN-201's technology is called Transduced Autologous Restorative Gene Therapy ((TARGT)). According to the company, TARGT enables greater cell uptake, less immunogenicity, improved safety and tolerability and lower cost than other gene therapies.
    | Jul. 15, 2015, 8:20 AM
  • Jun. 24, 2015, 12:45 PM
    | Jun. 24, 2015, 12:45 PM | 3 Comments
  • Apr. 17, 2015, 8:14 AM
    • Medgenics (MDGN -2.1%) Q1 results: Revenues: $0; R&D Expense: $3.9M (+85.7%); SG&A: $3.9M (+25.8%); Operating Loss: ($7.9M) (-51.9%); Net Loss: ($8.9M) (-64.8%); Loss Per Share: ($0.36) (-28.6%); Quick Assets: $25.2M (-24.3%).
    • No guidance given.
    | Apr. 17, 2015, 8:14 AM
Company Description
Medgenics, Inc. is a medical technology company, which develops protein therapeutics medical therapies. Its TARGT (Transduced Autologous Restorative Gene Therapy) platform is designed to provide sustained protein and peptide therapies to treat a range of chronic diseases and conditions. The... More
Sector: Healthcare
Industry: Biotechnology
Country: United States